[go: up one dir, main page]

HRP20100611T1 - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
HRP20100611T1
HRP20100611T1 HR20100611T HRP20100611T HRP20100611T1 HR P20100611 T1 HRP20100611 T1 HR P20100611T1 HR 20100611 T HR20100611 T HR 20100611T HR P20100611 T HRP20100611 T HR P20100611T HR P20100611 T1 HRP20100611 T1 HR P20100611T1
Authority
HR
Croatia
Prior art keywords
alkyl
pyrazol
ylmethyl
indan
methyl
Prior art date
Application number
HR20100611T
Other languages
Croatian (hr)
Inventor
Chhipa Laxmikant
Pukharaj Zambad Shitalkumar
Gupta Ramesh
Tuli Davinder
Kasundra Ashok
Munshi Siralee
Amir Siddiqui M.
Kumar Bhattamisra Subrat
Dutt C.
Chauthaiwale Vijay
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of HRP20100611T1 publication Critical patent/HRP20100611T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Spoj formule (I) naznačen time da, R1 i R3 je isti ili različit, te je nezavisno odabran od H, (C1-C6) alkil, (C3-C7) cikloalkil, halo, CN, OF3, -O-(C1-C6)alkil, -CO2-(C1-C6)alkil, COOH, -CONH-(C1-C6)alkil, -CONH-aril, -NH2, -CONH-R6,A compound of formula (I) wherein R 1 and R 3 are the same or different and are independently selected from H, (C 1 -C 6) alkyl, (C 3 -C 7) cycloalkyl, halo, CN, OF 3, -O- (C 1- C6) alkyl, -CO2- (C1-C6) alkyl, COOH, -CONH- (C1-C6) alkyl, -CONH-aryl, -NH2, -CONH-R6,

Claims (12)

1. Spoj formule (I) [image] naznačen time da, R1 i R3 je isti ili različit, te je nezavisno odabran od H, (C1-C6) alkil, (C3-C7) cikloalkil, halo, CN, OF3, -O-(C1-C6)alkil, -CO2-(C1-C6)alkil, COOH, -CONH-(C1-C6)alkil, -CONH-aril, -NH2, -CONH-R6, -CONR5, -C1-C3alkil-aril, -(C1-C3) alkil-R6, -NH-(C1-C6)alkil, -NHaril, -NH-SO2-(C1-C6)alkil, -CH2-NH-(C1-C6)alkil, -CH2-O-(C1-C6)alkil, -C1-C3alkil-NR5, R6, R7, pri čemu C1-C6alkil i C3-C7 cikloalkil su opcijski supstituirani sa jednim ili više supstituenata odabranih od (C1-C6)alkil, halo, cijano, -OH, okso, -COOH, -O-(C1-C6)alkil, -O-benzil, -COO-(C1-C6)alkil, -CONH-(C1-C6)alkil, -CONR5, -CONH-aril, -CONH-heteroaril ili -CH2NR5; R2 je odabran od (C1-C6)alkil, (C3-C6)cikloalkil, (C3-C6)alkenil, (C3-C6 )alkinil, -C(O)-(C1- C3)alkil-COOH, -(C1-C3)alkil-COOH, -C(O)-(C1-C3)alkil-COO-alkil, -C(O)-C(O)O-(C1-C6)alkil, -C(O)-(C1-C3 )alkil-NH-(C1-C6)alkil, -O(O)-O-(C1-C6)alkil, -C(O)NR5, -C(O)NH-(C1-C6)alkil, -C(O)-(C1-C3)alkilaril, -O(O)-(C1-C3)alkil-R6, R6, R7, pri čemu navedeni (C1-C6)alkil, (C3-C6 )cikloalkil, (C3-C6 )alkenil, (C3-C6)alkinil su opcijski supstituirani sa jednim ili više supstituenata odabranih od perhaloalkil, Okso, -C(O)OH, -C(O)-O-(C1-C3)alkil, -C(O)-O-(C1-C3)alkilaril, -C(O)-O-(C1-C3)alkil-R6, -CONH2,-CONH(C1-C3)alkil, -C(O)NH-aril, -C(O)NH- R6, -CONR5 -CONHNH2, -C(=NH)NH-(C1-C6)alkil, -C(=NH)NH2, C(=NH)NHOH, -C(O)-R8,-C(O)NHSO2(C1-C6) alkil, -C(O)NHSO2-aril, -C(O)NHOH, -C(O)NHSO2-R6, -C(O)NHNH-(C1-C6)alkil, -C(O)NHNH-aril, -CONH-(C1-C2)alkil-aril,-C(O)NH-(C1-C2) alkil-R6, -CH2NR5, -NH2, -NH-(C1-C6)alkil, -NH-C(O)-O-(C1-C3)alkil, -NH-C(O)-(C1-C3)alkil, -NHC(O)-aril, -NHC(O)-(C1-C3)alkilaril, - NHC(O)-R6, -NH-C(O)NR5, -NH-C(O)NH-aril, -NHC(O)NH-(C1-C6)alkil, - NHSO2(C1-C6)alkil, -NH-SO2-aril, -NH-SO2-R6, halo, cijano, -OH, -O-(C1-C6)alkil, -O-aril, -O-heteroaril, -O-(C1-C2)alkil-aril, -SO3H, -SO2NH-aril, - SO2NH-R6 ili -SO2NH-(C1-C6)alkil, R6 ili R7; R5 zajedno sa atomom dušika na kojeg je vezan tvore zasićeni ili nezasićeni (C3-C6) člani prsten, koji može nadalje sadržavati 1-2 heteroatoma odabranih od O, N ili S i koji može biti opcijski supstituiran sa jednim ili više supstituenata odabranih od okso, -COOH, halo,-OH, -O-(C1-C6)alkil, ili -(C1-C6)alkil; R6 je odabran od fenila ili 5-8 članog heteroarila koji sadrži 1-4 heteroatoma odabranih od O, N ili S, pri čemu navedeni heteroarilni ili fenilni prsten su opcijski supstituirani sa jednim ili više supstituenata odabranih od halogen, -OH, -O-(C1-C6)alkil, -perhaloalkil, -(C1-C6)alkil, -(C3-C6)cikloalkil, -SO2(C1-C6)alkil, cijano, -COOH, -C(O)O-(C1-C6)alkil, -C(O)O-CH2-aril, C(O)O-aril, -CONH(C1-C3)alkil, nitro, -NH2, -NH-(C1-C6)alkil, -NHC(O)- (C1-C6)alkil, -NHC(O)-aril, -NHSO2(C1-C5)alkil, -CONH2, -SO2-(C1-C6)alkil, - NHSO2(C1-C6)alkil ili -COR8; R7 je a 3-6 člani heterociklički prsten koji sadrži 1-4 heteroatoma odabranih od O, N ili S, i navedeni heterociklički prsten je opcijski supstituiran sa jednim ili više supstituenata odabranih od okso, halogen, -O-(C1-C6)alkil, -OH, - CF3, (C1-C6)alkil, (C3-C6)cikloalkil, cijano, -COOH, -C(O)O-(C1-C6)alkil, - C(O)O-CH2-aril, -C(O)O-aril, -NH2, -NH-(C1-C6)alkil, -NHC(O)-(C1-C6)alkil, - NHC(O)-aril, -CONH2, -SO2aril(C1-C6)alkil, -SO2-(C1-C6)alkil, -NHSO2(C1-C6)alkil ili -COR8; R8 je amino kiselina koja je povezana kroz njen atom dušika; Z = O, CH2 ili NH; R4 je odabran od P, Q ili T [image] Rg je odabran od -OH, -O-alkil, -OSO3H, halogen, -C(O)O-(C1-C6)alkil,-C(O)NHR8, -OC(O)-(C1-C6)alkil, -O-perhaloalkil, -OC(O)O-(C1-C6)alkil,-CONR5 ,-NHCO-(C1-C6)alkil, -NHC(O)-O-(C1-C6)alkil, -NHC(O)-O-aril,-NHSO2-(C1-C6)alkil, -NHSO2-aril, -NHCONR5 ili; [image] R10 je odabran od H, Halogen, (C1-C6)alkil, alkoksi, ariloksi, -NHCO-(C1-C6)alkil, -NHSO2-(C1-C6)alkil ili -NH-SO2-aril; R11 je -CO-(C1-C6)alkil, -SO2-(C1-C6)alkil ili -SO2-aril; G' je odabran od H, halogena ili (C1-C6)alkila; G" je odabran od vodika, (C1-C6)alkila, (C3-C6)cikloalkila, arila, halogena, perhaloalkila, CN, CHO, -(C1-C3)alkilarila, -(C1-C6)alkil-O-(C1-C6)alkila, -CH2R9, -CH2arila, -CH2NR5, -COOH, -C(O)O(C1-C6)alkila, -CONH-(C1-C6)alkila,-CONR5, -SO2NR5, -SO2NH-(C1-C6)alkila, -SO2NH-aril; n može biti jedan ili dva; pod uvjetom da: kada R4 je Q tada R2 je osim R6 i R7; uključujući njihove farmaceutski prihvatljive soli i njihove hidrate, solvate, atropizomere, regioizomere, enantiomere, diastereomere, tautomere i njihove polimorfe.1. Compound of formula (I) [image] indicated that R1 and R3 are the same or different, and are independently selected from H, (C1-C6) alkyl, (C3-C7) cycloalkyl, halo, CN, OF3, -O-(C1-C6)alkyl, - CO2-(C1-C6)alkyl, COOH, -CONH-(C1-C6)alkyl, -CONH-aryl, -NH2, -CONH-R6, -CONR5, -C1-C3alkyl-aryl, -(C1-C3) alkyl-R6, -NH-(C1-C6)alkyl, -NHaryl, -NH-SO2-(C1-C6)alkyl, -CH2-NH-(C1-C6)alkyl, -CH2-O-(C1-C6 )alkyl, -C1-C3alkyl-NR5, R6, R7, wherein C1-C6alkyl and C3-C7 cycloalkyl are optionally substituted with one or more substituents selected from (C1-C6)alkyl, halo, cyano, -OH, oxo, -COOH, -O-(C1-C6)alkyl, -O-benzyl, -COO-(C1-C6)alkyl, -CONH-(C1-C6)alkyl, -CONR5, -CONH-aryl, -CONH-heteroaryl or -CH 2 NR 5 ; R2 is selected from (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)alkenyl, (C3-C6)alkynyl, -C(O)-(C1-C3)alkyl-COOH, -(C1 -C3)alkyl-COOH, -C(O)-(C1-C3)alkyl-COO-alkyl, -C(O)-C(O)O-(C1-C6)alkyl, -C(O)-( C1-C3 )alkyl-NH-(C1-C6)alkyl, -O(O)-O-(C1-C6)alkyl, -C(O)NR5, -C(O)NH-(C1-C6)alkyl , -C(O)-(C1-C3)alkylaryl, -O(O)-(C1-C3)alkyl-R6, R6, R7, wherein said (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)alkenyl, (C3-C6)alkynyl are optionally substituted with one or more substituents selected from perhaloalkyl, Oxo, -C(O)OH, -C(O)-O-(C1-C3)alkyl, - C(O)-O-(C1-C3)alkylaryl, -C(O)-O-(C1-C3)alkyl-R6, -CONH2,-CONH(C1-C3)alkyl, -C(O)NH- aryl, -C(O)NH- R6, -CONR5 -CONHNH2, -C(=NH)NH-(C1-C6)alkyl, -C(=NH)NH2, C(=NH)NHOH, -C(O )-R8, -C(O)NHSO2(C1-C6) alkyl, -C(O)NHSO2-aryl, -C(O)NHOH, -C(O)NHSO2-R6, -C(O)NHNH-( C1-C6)alkyl, -C(O)NHNH-aryl, -CONH-(C1-C2)alkyl-aryl, -C(O)NH-(C1-C2)alkyl-R6, -CH2NR5, -NH2, - NH-(C1-C6)alkyl, -NH-C(O)-O-(C1-C3)alkyl, -NH-C(O)-(C1-C3)alkyl, -NHC(O)-aryl, - NHC(O)-(C1-C3)alkylaryl, - NHC (O)-R6, -NH-C(O)NR5, -NH-C(O)NH-aryl, -NHC(O)NH-(C1-C6)alkyl, - NHSO2(C1-C6)alkyl, - NH-SO2-aryl, -NH-SO2-R6, halo, cyano, -OH, -O-(C1-C6)alkyl, -O-aryl, -O-heteroaryl, -O-(C1-C2)alkyl- aryl, -SO3H, -SO2NH-aryl, -SO2NH-R6 or -SO2NH-(C1-C6)alkyl, R6 or R7; R5 together with the nitrogen atom to which it is attached form a saturated or unsaturated (C3-C6) membered ring, which may further contain 1-2 heteroatoms selected from O, N or S and which may be optionally substituted with one or more substituents selected from oxo , -COOH, halo, -OH, -O-(C1-C6)alkyl, or -(C1-C6)alkyl; R6 is selected from phenyl or 5-8 membered heteroaryl containing 1-4 heteroatoms selected from O, N or S, wherein said heteroaryl or phenyl ring is optionally substituted with one or more substituents selected from halogen, -OH, -O- (C1-C6)alkyl, -perhaloalkyl, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -SO2(C1-C6)alkyl, cyano, -COOH, -C(O)O-(C1- C6)alkyl, -C(O)O-CH2-aryl, C(O)O-aryl, -CONH(C1-C3)alkyl, nitro, -NH2, -NH-(C1-C6)alkyl, -NHC( O)-(C1-C6)alkyl, -NHC(O)-aryl, -NHSO2(C1-C5)alkyl, -CONH2, -SO2-(C1-C6)alkyl, -NHSO2(C1-C6)alkyl or - COR8; R7 is a 3-6 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N or S, and said heterocyclic ring is optionally substituted with one or more substituents selected from oxo, halogen, -O-(C1-C6)alkyl , -OH, - CF3, (C1-C6)alkyl, (C3-C6)cycloalkyl, cyano, -COOH, -C(O)O-(C1-C6)alkyl, - C(O)O-CH2-aryl , -C(O)O-aryl, -NH2, -NH-(C1-C6)alkyl, -NHC(O)-(C1-C6)alkyl, - NHC(O)-aryl, -CONH2, -SO2aryl( C1-C6)alkyl, -SO2-(C1-C6)alkyl, -NHSO2(C1-C6)alkyl or -COR8; R8 is an amino acid linked through its nitrogen atom; Z = O, CH 2 or NH; R 4 is selected from P, Q or T [image] Rg is selected from -OH, -O-alkyl, -OSO3H, halogen, -C(O)O-(C1-C6)alkyl, -C(O)NHR8, -OC(O)-(C1-C6)alkyl, - O-perhaloalkyl, -OC(O)O-(C1-C6)alkyl, -CONR5 ,-NHCO-(C1-C6)alkyl, -NHC(O)-O-(C1-C6)alkyl, -NHC(O )-O-aryl, -NHSO2-(C1-C6)alkyl, -NHSO2-aryl, -NHCONR5 or; [image] R 10 is selected from H, Halogen, (C 1 -C 6 )alkyl, alkoxy, aryloxy, -NHCO-(C 1 -C 6 )alkyl, -NHSO 2 -(C 1 -C 6 )alkyl or -NH-SO 2 -aryl; R 11 is -CO-(C 1 -C 6 )alkyl, -SO 2 -(C 1 -C 6 )alkyl or -SO 2 -aryl; G' is selected from H, halogen or (C1-C6)alkyl; G" is selected from hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, halogen, perhaloalkyl, CN, CHO, -(C1-C3)alkylaryl, -(C1-C6)alkyl-O-( C1-C6)alkyl, -CH2R9, -CH2aryl, -CH2NR5, -COOH, -C(O)O(C1-C6)alkyl, -CONH-(C1-C6)alkyl, -CONR5, -SO2NR5, -SO2NH- (C1-C6)alkyl, -SO2NH-aryl, n may be one or two; under condition: when R4 is Q then R2 is apart from R6 and R7; including their pharmaceutically acceptable salts and their hydrates, solvates, atropisomers, regioisomers, enantiomers, diastereomers, tautomers and polymorphs thereof. 2. Spoj prema zahtjevu 1, naznačen time da R4 je odabran od P ili T.2. A compound according to claim 1, characterized in that R4 is selected from P or T. 3. Spoj naznačen time da je odabran iz skupine koja se sastoji od: 1 3-[4-(7-Hidroksi-indan-4-iloksi)-3, 5-dimetil-pirazol-1-il]-propionske kiseline 2 3-[4-(1H-indol-5-ilmetil)-3, 5-dimetil-pirazol-1-il]-propionske kiseline 3 7-[3, 5-Dimetil-1-(1H-tetrazol-5-ilmetil)-1H-pirazol-4-iloksi]-indan-4-ola 4: 7-{3, 5-Dimetil-1-[2-(1H-tetrazol-5-il)-etil]-1H-pirazol-4-iloksi}-indan-4-ola 5 {2-[4-(7-Hidroksi-indan-4-iloksi)-3, 5-dimetil-pirazol-1-il]-acetil amino}-octene kiseline 6: 2-[4-(7-Hidroksi-indan-4-iloksi)-3, 5-dimetil-pirazol-1-il]-N-(1H-tetrazol-5-il)-acetamida 7 3-[4-(7-Hidroksi-indan-4-iloksi)-3-tiofen-2-il-pirazol-1-il]-propionske kiseline i 3-[4-(7-Hidroksi-indan-4-iloksi)-5-tiofen-2-il-pirazol-1-il]-propionske kiseline 8 7-[1-(1H-Tetrazol-5-ilmetil)-3-tiofen-2-il-1H-pirazol-4-iloksi]-lndan-4-ola i 7-[1-(1H-Tetrazol-5-ilmetil)-5-tiofen-2-il-1H-pirazol-4-iloksi]-indan-4-ola 9 3-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3, 5-dimetil-pirazol-1-il]-propionske kiseline 10 5-[4-(7-Hidroksi-indan-4-iloksi)-3,5-dimetil-pirazol-1-ilmetil]-1H-pirazol-3-ola 11 2-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3, 5-dimetil-pirazol-1-il]-octene kiseline 12 7-[1-(2-Hidroksi-etil)-3,5-dimetil-1H-pirazol-4-ilmetil]-5-metil-indan-4-ola 13 [4-(1H-Indol-5-ilmetil)-3,5-dimetil-pirazol-1-il]-octene kiseline 14 3-[4-(7-Metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]- propionske kiseline 15 7-[3,5-Dimetil-1-(1H-tetrazol-5-ilmetil)-1H-pirazol-4-ilmetil]-5-metil-indan-4-ola 16 7-[3,5-Diizopropil-1-(1H-tetrazol-5-ilmetil)-1H-pirazol-4-ilmetil]-5-metil-indan-4-ola 17 3-[3,5-Diciklopropil-4-(7-hidroksi-indan-4-iloksi)-pirazol-1-il]-propionske kiseline 18 3-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-diizopropil-pirazol-1-il]-propionske kiseline 19 [3,5-Dietil-4-(7-hidroksi-6-metil-indan-4-ilmetil)-pirazol-1-il]-octene kiseline 20 3-[3,5-Dietil-4-(7-hidroksi-6-metil-indan-4-ilmetil)-pirazol-1-il]-propionske kiseline 21 7-[3,5-Dietil-1-(1H-tetrazol-5-ilmetil)-1H-pirazol-4-ilmetil]-5-metil-indan-4-ola 22 [3,5-Diciklopropil-4-(7-hidroksi-indan-4-iloksi)-pirazol-1-il]-octene kiseline 23 3-[3,5-Dietil-4-(1H-indol-5-ilmetil)-pirazol-1-il]-propionske kiseline 24 2-[4-(1H-Indol-5-ilmetil)-3,5-dimetil-pirazol-1-il]-etanola 25 [4-(7-Hidroksi-indan-4-iloksi)-3,5-dimetil-pirazol-1-il]-octene kiseline 26 3-[4-(6-Kloro-7-hidroksi-indan-4-ilmetil)-3,5-dietil-pirazol-1-il]-propionske kiseline 27 [4-(6-Kloro-7-hidroksi-indan-4-ilmetil)-3,5-dietil-pirazol-1-il]-octene kiseline 28 3-{4-17-Hidroksi-6-(pirolidine-1-karbonil)-indan-4-ilmetil]-3,5-dimetil-pirazol-1-il}-propionske kiseline 29 3-[4-(6-Kloro-7-hidroksi-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-propionske kiseline 30 1-{2-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-acetil}-pirolidin-2-karboksilne kiseline 31 7-[3,5-Dimetil-1-(1H-tetrazol-5-ilmetil)-1H-pirazol-4-iloksil-5-metil-indan-4-ola 32 [4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-diizopropil-pirazol-1-il]-octene kiseline 33 3-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-N-izopropil-propionamida 34 [4-(7-Hidroksi-6-metil-indan-4-iloksi)-3,5-dimetil-pirazol-1-il]-octene kiseline 35 3-[4-(7-Hidroksi-6-metil-indan-4-iloksi)-3,5-dimetil-pirazol-1-il]-propionske kiseline 36 4-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-maslačne kiseline 37 3-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-N-(1 H-tetrazol-5-il)-propionamida 38 5-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-ilmetil]-3H-[1,3,4]oksadiazol-2-ona 39 7-{3,5-Dimetil-1-[2-(1H-tetrazol-5-il)-etil]-1H-pirazol-4-ilmetil}-5-metil-indan-4-ola 40 {2-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetyl-pirazol-1-il]-acetilamino}-octene kiseline 41 5-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-ilmetil]-1H-pirazol-3-ola 42 5-[3,5-Dietil-4-(7-hidroksi-6-metil-indan-4-ilmetil)-pirazol-1-ilmetil]-3H-[1,3,4]oksadiazol-2-ona 43 5-{2-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-etil}-3H-[1,3,4]oksadiazol-2-ona 44 {2-[3,5-Dietil-4-(7-hidroksi-6-metil-indan-4-ilmetil)-pirazol-1-il]-acetilamino}-octene kiseline 45 6-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-ilmetl]-2-metil-3H-pirimidin-4-ona 46 3-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-ilmetil]-[1,2,4]oksadiazol-5-ola 47 7-(1-Benzil-3,5-dimetil-1H-pirazol-4-ilmetil)-5-metil-indan-4-ola 48 3-{4-[7-Hidroksi-6-(4-metil-benzil)-indan-4-ilmetil]-3,5-dimetil-pirazol-1-il}-propionske kiseline 49 2-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-propionske kiseline 50 3-[4-(7-Hidroksi-6-izopropil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-propionske kiseline 51 {4-[7-Hidroksi-6-(4-metil-benzil)-indan-4-ilmetil]-3,5-dimetil-pirazol-1-il}-octene kiseline 52 3-{4-[6-(4-Fluoro-benzil)-7-hidroksi-indan-4-ilmetil]-3,5-dimetil-pirazol-1-il}-propionske kiseline 53 {4-[6-(4-Fiuoro-benzil)-7-hidroksi-indan-4-ilmetil]-3,5-dimetil-pirazol-1-il}-octene kiseline 54 Natrijeva sol 4-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-maslačne kiseline, 55 Magnezijeva sol 3-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-propionske kiseline 56 Natrijeva sol 3-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3, 5-dimetil-pirazol-1-il]-propionske kiseline, 57 3-{3,5-Dietil-4-[6-(4-fluoro-benzil)-7-hidroksi-indan-4-ilmetil]-pirazol-1-il}-propionske kiseline 58 3-[4-(7-Metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-3-okso-propionska kiselina etil estera 59 [3,5-Dietil-4-(7-metoksi-6-metil-indan-4-ilmety)-pirazol-1-il]-octene kiseline hidrazida 60 N-Hidroksi-2-[4-(7-metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-acetamidina 61 [4-(7-Metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-okso-octena kiselina etil estera 62 [4-(7-Metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-morfolin-4-il-metanona 63 1-(4-Kloro-fenil)-4-(7-metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-1H-pirazola 64 2-(4-Metanesulfonil-fenil)-1-[4-(7-metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-etanona 65 4-(7-Metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-karboksilna kiselina etil estera 66 Propan-2-sulfonska kiselina {3-[4-(7-metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-propionil}-amid 67 3-[5-Etoksi-4-(7-metoksi-6-metil- indan-4-ilmetil)-3-metil-pirazol-1-il]-propionske kiseline ili 3-[3-Etoksi-4-(7-metoksi-6-metil- indan-4-ilmetil)-5-metil-pirazol-1-il]-propionske kiseline 68 [4-(7-Hidroksi-3,6-dimetil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-octene kiseline 69 2-[4-(7-Hidroksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-ilmetil]-pentandionske kiseline 70 [4-(7-Metoksi-2,2,6-trimetil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-octene kiseline 71 N-{2-[4-(7-Metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-etil}-acetamida 72 N-{2-[4-(7-Metoksi-6-metil-indan-4-ilmetil)-3,5-dimetil-pirazol-1-il]-etil}-metansulfonamida 73 4-[4-(7-Metoksi-6-metil-indan,4-ilmetil)-3,5-dimetil-pirazol-1-il]-1-(toluen-4-sulfonil)-piperidina 74 {3,5-Dietil-4-[6-(4-fluoro-benzil)-7-hidroksi-indan-4-ilmetil]-pirazol-1-il}-octene kiseline 75 3-{4-[7-Metoksi-6-(4-metoksi-fenil)-indan-4-ilmetil]-3,5-dimetil-pirazol-1-il}-propionske kiseline 76 2-[3,5-Dietil-4-(7-hidroksi-6-metil-indan-4-ilmetil)-pirazol-1-il]-N-izopropil-acetamida 77 3-[4-(7-Etoksikarboniloksi-6-metil-indan-4-ilmetil)-3,5-dimetil, pirazol-1-il]-propionske kiseline metil estera 78 Natrijeva sol [3,5-Dietil-4-(7-hidroksi-6-metil-indan-4-ilmetil)-pirazol-1-il]-octene kiseline 79 3-[4-(7-Metoksi-6-metil-indan-4-ilmetil)-3-metil-5-trifluorometil-parazol-1-il]-propionske kiseline i 3-[4(7-Metoksi-6-metil-indan-4-ilmetil)-5-metil-3-trifluorometil-pirazol-1-il]-propionske kiseline 80 [4-(4-Hidroksi-3-metil-5,6,7,8-tetrahidro-naftalen-1-ilmetil)-3,5-dimetil-pirazol-1-il]-octene kiseline 81 [4-(7-Kloro-indan-4-iloksi)-3-tiofen-2-il-pirazol-1-il]-octene kiseline i [4-(7-Kloro-indan-4-iloksi)-5-tiofen-2-il-pirazol-1-il]-octene kiseline 82 {4-[7-Metoksi-6-metil-2-(4-nitro- fenoksi)-indan-4-ilmetil]- 3,5-dimetil-pirazol-1-il}-octene kiseline 83 [5-Amino-4-(7-metoksi-6-metil-indan-4-ilmetil)-3-(4-metoksifenil)-pirazol-1-il]-octene kiseline i [3-Amino-4-(7-metoksi-6-metil-indan-4-ilmetil)-5-(4-metoksifenil)-pirazol-1-il]-octene kiseline 84 2-[3,5-Dietil-4-(7-hidroksi-6- metil-indan-4-ilmetil)- pirazol-1-il]-N-(1H-tetrazol-5-il)-acetamida 85 1-Karboksimetil-5-(5-kloro-tiofen-2-il)-4-(7-metoksi-6-metil-indan-4-ilmetil)-1H-pirazol-3-karboksilne kiseline i 2-Karboksimetil-5-(5-kloro-tiofen-2-il)-4-(7-metoksi-6-metil-indan-4-ilmetil)-2H-pirazol-3-karboksilne kiseline 86 3-[4-(1H-indol-5-iloksi)-3,5-dimetil-pirazol-1-il]-propionske kiseline 87 [4-(1H-indol-5-iloksi)-3,5-dimetil-pirazol-1-il]-octene kiseline 88 2-[4-(7-Hidroksi-indan-4-iloksi)-3,5-dimetil-pirazol-1-il]-propionske kiseline 89 1-{2-[3,5-Dietil-4-(7-hidroksi-6-metil-indan-4-ilmetil)-pirazol-1-il]-acetil}-pirolidin-2-karboksilne kiseline 90 [3,5-Dietil-4-(7-hidroksi-6-pirrolidin-1-ilmetil-indan-4-ilmetil)-pirazol-1-il]-octene kiseline 91 3-[3,5-Dietil-4-(7-hidroksi-6-pirrolidin-1-ilmetil-indan-4-ilmetil)-pirazol-1-il]-propionske kiseline 92 3-[3,5-Dietil-4-(7-metoksi-6-metoksimetil-indan-4-ilmetil)-pirazol-1-il]-propionske kiseline 93 {3,5-Dietil-4-[7-hidroksi-6-(pirolidin-1-karbonil)-indan-4-ilmetil]-pirazol-1-il}-octene kiseline 94 [3,5-Dietil-4-(7-metoksi-6-metoksimetil-indan-4-ilmetil)-pirazol-1-il]-octene kiseline 95 3-{3,5-Dietil-4-[7-hidroksi-6-(pirolidin-1-karbonil)-indan-4-ilmetil]-pirazol-1-il}-propionske kiseline 96 N-(4-Kloro-fenil)-2-[3,5-dietil-4-(7-hidroksi-6-metil-indan-4-ilmetil)-pirazol-1-il]-acetamida.3. A compound selected from the group consisting of: 1 3-[4-(7-Hydroxy-indan-4-yloxy)-3, 5-dimethyl-pyrazol-1-yl]-propionic acid 2 3-[4-(1H-indol-5-ylmethyl)-3, 5-dimethyl-pyrazol-1-yl]-propionic acid 3 7-[3, 5-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-yloxy]-indan-4-ol 4: 7-{3, 5-Dimethyl-1-[2-(1H-tetrazol-5-yl)-ethyl]-1H-pyrazol-4-yloxy}-indan-4-ol 5 {2-[4-(7-Hydroxy-indan-4-yloxy)-3, 5-dimethyl-pyrazol-1-yl]-acetyl amino}-acetic acid 6: 2-[4-(7-Hydroxy-indan-4-yloxy)-3, 5-dimethyl-pyrazol-1-yl]-N-(1H-tetrazol-5-yl)-acetamide 7 3-[4-(7-Hydroxy-indan-4-yloxy)-3-thiophen-2-yl-pyrazol-1-yl]-propionic acid and 3-[4-(7-Hydroxy-indan-4- yloxy)-5-thiophen-2-yl-pyrazol-1-yl]-propionic acid 8 7-[1-(1H-Tetrazol-5-ylmethyl)-3-thiophen-2-yl-1H-pyrazol-4-yloxy]-lndan-4-ol and 7-[1-(1H-Tetrazol-5 -ylmethyl)-5-thiophen-2-yl-1H-pyrazol-4-yloxy]-indan-4-ol 9 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3, 5-dimethyl-pyrazol-1-yl]-propionic acid 10 5-[4-(7-Hydroxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-ylmethyl]-1H-pyrazol-3-ol 11 2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3, 5-dimethyl-pyrazol-1-yl]-acetic acid 12 7-[1-(2-Hydroxy-ethyl)-3,5-dimethyl-1H-pyrazol-4-ylmethyl]-5-methyl-indan-4-ol 13 [4-(1H-Indol-5-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetic acid 14 3-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]- propionic acid 15 7-[3,5-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-ylmethyl]-5-methyl-indan-4-ol 16 7-[3,5-Diisopropyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-ylmethyl]-5-methyl-indan-4-ol 17 3-[3,5-Dicyclopropyl-4-(7-hydroxy-indan-4-yloxy)-pyrazol-1-yl]-propionic acid 18 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-diisopropyl-pyrazol-1-yl]-propionic acid 19 [3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid 20 3-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-propionic acid 21 7-[3,5-Diethyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-ylmethyl]-5-methyl-indan-4-ol 22 [3,5-Dicyclopropyl-4-(7-hydroxy-indan-4-yloxy)-pyrazol-1-yl]-acetic acid 23 3-[3,5-Diethyl-4-(1H-indol-5-ylmethyl)-pyrazol-1-yl]-propionic acid 24 2-[4-(1H-Indol-5-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethanol 25 [4-(7-Hydroxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-acetic acid 26 3-[4-(6-Chloro-7-hydroxy-indan-4-ylmethyl)-3,5-diethyl-pyrazol-1-yl]-propionic acid 27 [4-(6-Chloro-7-hydroxy-indan-4-ylmethyl)-3,5-diethyl-pyrazol-1-yl]-acetic acid 28 3-{4-17-Hydroxy-6-(pyrrolidine-1-carbonyl)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-propionic acid 29 3-[4-(6-Chloro-7-hydroxy-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid 30 1-{2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetyl}-pyrrolidine-2-carboxylic acids 31 7-[3,5-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-yloxyl-5-methyl-indan-4-ol 32 [4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-diisopropyl-pyrazol-1-yl]-acetic acid 33 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-N-isopropyl-propionamide 34 [4-(7-Hydroxy-6-methyl-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-acetic acid 35 3-[4-(7-Hydroxy-6-methyl-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-propionic acid 36 4-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-butyric acid 37 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-N-(1 H-tetrazol-5-yl)-propionamide 38 5-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-3H-[1,3,4]oxadiazol-2-one 39 7-{3,5-Dimethyl-1-[2-(1H-tetrazol-5-yl)-ethyl]-1H-pyrazol-4-ylmethyl}-5-methyl-indan-4-ol 40 {2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetylamino}-acetic acid 41 5-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-1H-pyrazol-3-ol 42 5-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-ylmethyl]-3H-[1,3,4]oxadiazol-2-one 43 5-{2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethyl}-3H-[1,3,4] oxadiazol-2-one 44 {2-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetylamino}-acetic acid 45 6-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-2-methyl-3H-pyrimidin-4-one 46 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-[1,2,4]oxadiazol-5-ol 47 7-(1-Benzyl-3,5-dimethyl-1H-pyrazol-4-ylmethyl)-5-methyl-indan-4-ol 48 3-{4-[7-Hydroxy-6-(4-methyl-benzyl)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-propionic acid 49 2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid 50 3-[4-(7-Hydroxy-6-isopropyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid 51 {4-[7-Hydroxy-6-(4-methyl-benzyl)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-acetic acid 52 3-{4-[6-(4-Fluoro-benzyl)-7-hydroxy-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-propionic acid 53 {4-[6-(4-Fluoro-benzyl)-7-hydroxy-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-acetic acid 54 Sodium salt of 4-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-butyric acid, 55 Magnesium salt of 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid 56 Sodium salt of 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3, 5-dimethyl-pyrazol-1-yl]-propionic acid, 57 3-{3,5-Diethyl-4-[6-(4-fluoro-benzyl)-7-hydroxy-indan-4-ylmethyl]-pyrazol-1-yl}-propionic acid 58 3-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-3-oxo-propionic acid ethyl ester 59 [3,5-Diethyl-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid hydrazide 60 N-Hydroxy-2-[4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetamidine 61 [4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-oxo-acetic acid ethyl ester 62 [4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-morpholin-4-yl-methanone 63 1-(4-Chloro-phenyl)-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-1H-pyrazole 64 2-(4-Methanesulfonyl-phenyl)-1-[4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethanone 65 4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazole-1-carboxylic acid ethyl ester 66 Propane-2-sulfonic acid {3-[4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionyl}-amide 67 3-[5-Ethoxy-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3-methyl-pyrazol-1-yl]-propionic acid or 3-[3-Ethoxy-4-( 7-Methoxy-6-methyl-indan-4-ylmethyl)-5-methyl-pyrazol-1-yl]-propionic acid 68 [4-(7-Hydroxy-3,6-dimethyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetic acid 69 2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-pentanedioic acid 70 [4-(7-Methoxy-2,2,6-trimethyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetic acid 71 N-{2-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethyl}-acetamide 72 N-{2-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethyl}-methanesulfonamide 73 4-[4-(7-Methoxy-6-methyl-indan,4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-1-(toluene-4-sulfonyl)-piperidine 74 {3,5-Diethyl-4-[6-(4-fluoro-benzyl)-7-hydroxy-indan-4-ylmethyl]-pyrazol-1-yl}-acetic acid 75 3-{4-[7-Methoxy-6-(4-methoxy-phenyl)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-propionic acid 76 2-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-N-isopropyl-acetamide 77 3-[4-(7-Ethoxycarbonyloxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl, pyrazol-1-yl]-propionic acid methyl ester 78 Sodium salt of [3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid 79 3-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3-methyl-5-trifluoromethyl-parazol-1-yl]-propionic acid and 3-[4(7-Methoxy-6 -methyl-indan-4-ylmethyl)-5-methyl-3-trifluoromethyl-pyrazol-1-yl]-propionic acid 80 [4-(4-Hydroxy-3-methyl-5,6,7,8-tetrahydro-naphthalen-1-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetic acid 81 [4-(7-Chloro-indan-4-yloxy)-3-thiophen-2-yl-pyrazol-1-yl]-acetic acid and [4-(7-Chloro-indan-4-yloxy)-5 -thiophen-2-yl-pyrazol-1-yl]-acetic acid 82 {4-[7-Methoxy-6-methyl-2-(4-nitro-phenoxy)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-acetic acid 83 [5-Amino-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3-(4-methoxyphenyl)-pyrazol-1-yl]-acetic acid and [3-Amino-4-( 7-Methoxy-6-methyl-indan-4-ylmethyl)-5-(4-methoxyphenyl)-pyrazol-1-yl]-acetic acid 84 2-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-N-(1H-tetrazol-5-yl)-acetamide 85 1-Carboxymethyl-5-(5-chloro-thiophen-2-yl)-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-1H-pyrazole-3-carboxylic acids and 2-Carboxymethyl- 5-(5-chloro-thiophen-2-yl)-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-2H-pyrazole-3-carboxylic acids 86 3-[4-(1H-indol-5-yloxy)-3,5-dimethyl-pyrazol-1-yl]-propionic acid 87 [4-(1H-indol-5-yloxy)-3,5-dimethyl-pyrazol-1-yl]-acetic acid 88 2-[4-(7-Hydroxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-propionic acid 89 1-{2-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetyl}-pyrrolidine-2-carboxylic acids 90 [3,5-Diethyl-4-(7-hydroxy-6-pyrrolidin-1-ylmethyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid 91 3-[3,5-Diethyl-4-(7-hydroxy-6-pyrrolidin-1-ylmethyl-indan-4-ylmethyl)-pyrazol-1-yl]-propionic acid 92 3-[3,5-Diethyl-4-(7-methoxy-6-methoxymethyl-indan-4-ylmethyl)-pyrazol-1-yl]-propionic acid 93 {3,5-Diethyl-4-[7-hydroxy-6-(pyrrolidin-1-carbonyl)-indan-4-ylmethyl]-pyrazol-1-yl}-acetic acid 94 [3,5-Diethyl-4-(7-methoxy-6-methoxymethyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid 95 3-{3,5-Diethyl-4-[7-hydroxy-6-(pyrrolidin-1-carbonyl)-indan-4-ylmethyl]-pyrazol-1-yl}-propionic acid 96 N-(4-Chloro-phenyl)-2-[3,5-diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetamide. 4. Farmaceutski pripravak naznačen time da sadrži terapeutski učinkovitu količinu jednog ili više spojeva prema zahtjevu 1 ili 3, opcionalno u kombinaciji s farmaceutski prihvatljivim solima, otapalima ili nosačima.4. Pharmaceutical preparation characterized in that it contains a therapeutically effective amount of one or more compounds according to claim 1 or 3, optionally in combination with pharmaceutically acceptable salts, solvents or carriers. 5. Upotreba jednog ili više spojeva prema zahtjevu 1 ili 3, naznačena time da je za proizvodnju lijeka za liječenje pretilosti kod živih sisavaca, uključujući ljudska bića.5. Use of one or more compounds according to claim 1 or 3, characterized in that it is for the production of a drug for the treatment of obesity in living mammals, including human beings. 6. Upotreba jednog ili više spojeva prema zahtjevu 1 ili 3, naznačena time da je za proizvodnju lijeka za poboljšavanje inzulinske rezistencije i/ili sprečavanje ili odlaganje progresije neposrednog dijabetesa kod živih sisavaca, uključujući ljudska bića.6. The use of one or more compounds according to claim 1 or 3, characterized in that it is for the production of a drug for improving insulin resistance and/or preventing or delaying the progression of immediate diabetes in living mammals, including human beings. 7. Upotreba jednog ili više spojeva prema zahtjevu 1 ili 3, naznačena time da je za proizvodnju lijeka za prevenciju i liječenje dislipidemije kod živih sisavaca, uključujući ljudska bića.7. Use of one or more compounds according to claim 1 or 3, characterized in that it is for the production of a drug for the prevention and treatment of dyslipidemia in living mammals, including human beings. 8. Upotreba jednog ili više spojeva prema zahtjevu 1 ili 3, naznačena time da je za proizvodnju lijeka za prevenciju i liječenje metaboličkog sindroma kod živih sisavaca, uključujući ljudska bića.8. The use of one or more compounds according to claim 1 or 3, characterized in that it is for the production of a drug for the prevention and treatment of metabolic syndrome in living mammals, including human beings. 9. Upotreba jednog ili više spojeva prema zahtjevu 1 ili 3, naznačena time da je za proizvodnju lijeka za prevenciju i liječenje bolesti ili poremećaja povezanih s neuravnoteženom aktivnošću hormona štitnjače kod živih sisavaca, uključujući ljudska bića.9. The use of one or more compounds according to claim 1 or 3, characterized in that it is for the production of a drug for the prevention and treatment of diseases or disorders associated with unbalanced thyroid hormone activity in living mammals, including human beings. 10. Upotreba prema zahtjevu 9, naznačena time da je bolest ili poremećaj odabran od 1) stanja povezanih sa prekomjernim nakupljanjem masnoća, promjenom mitohondrijske funkcije, 2) lipidnih poremećaja uzrokovanih neravnotežom razine lipida u krvi ili tkivu 3) poremećenom tolerancijom glukoze 4) dijabetesom tipa II 5) zamjenskom terapijom starijih osoba s hipotireozom 6) depresijom 7) kardiovaskularnim bolestima i 8 ) kožnim poremećajima.10. Use according to claim 9, characterized in that the disease or disorder is selected from 1) conditions associated with excessive fat accumulation, changes in mitochondrial function, 2) lipid disorders caused by an imbalance of lipid levels in the blood or tissue 3) impaired glucose tolerance 4) type 2 diabetes II 5) replacement therapy of elderly people with hypothyroidism 6) depression 7) cardiovascular diseases and 8) skin disorders. 11. Spoj formule (IA) naznačen time da je za upotrebu u postupku liječenja bolesnih stanja povezanih sa neprimjerenom aktivnošću hormona štitnjače odabranih od pretilosti, inzulinske rezistencije, dislipidemije, metaboličkog sindroma, dijabetesa tipa II, zamjenske terapije starijih osoba s hipotireozom, depresijom, kardiovaskularnim bolestima i poremećajima kože primjenom terapeutski učinkovite količine spoja u živih sisavaca, uključujući i ljudska bića: [image] pri čemu, R1 i R3 je isti ili različit, i nezavisno je odabran od H, (C1-C6) alkil, (C3-C7) cikloalkila, halo, CN, CF3, -O-(C1-C6)alkil, -CO2-(C1-C6)alkil, COOH, -CONH-(C1-C6)alkil, -CONH-aril, -NH2, -CONH-R6,-CONR5, -C1-C3alkil-aril, -(C1-C3) alkil-R6, -NH-(C1-C6)alkil, -NHaril, -NH-SO2-(C1-C6)alkil, -CH2-NH-(C1-C6)alkil, -CH2-O-(C1-C6)alkil, -C1-C3alkil-NR5, R6, R7, pri čemu C1-C6alkil i C3-C7 cikloalkil je opcijski supstituirani sa jednim ili više supstituenata odabranih od (C1-C6)alkil, halo, cijano, -OH, okso, -COOH, -O-(C1-C6)alkil, -O-benzil, -COO-(C1-C6)alkil, -CONH-(C1-C6)alkil, -CONR5, -CONH-aril, -CONH-heteroaril ili -CH2NR5; R2 je odabran od (C1-C6)alkil, (C3-C6)cikloalkil, (C3-C6)alkenil, (C3-C6 )alkinil, -C(O)-(C1- C3)alkil-COOH, -(C1- C3)alkil-COOH, -C(O)-(C1-C3)alkil-COO-alkil, -C(O)-C(O)O-(C1-C6)alkil, -C(O)-(C1-C3 )alkil-NH-(C1-C6)alkil, -C(O)-O-(C1-C6)alkil, -C(O)NR5, -C(O)NH-(C1-C6)alkil, -C(O)-(C1-C3)alkilaril, -C(O)-(C1-C3)alkil-R6, R6, R7, pri čemu navedeni (C1-C6)alkil, (C3-C6 )cikloalkil, (C3-C6)alkenil, (C3-C6)alkinil su opcijski supstituirani sa jednim ili više supstituenata odabranih od perhaloalkil, Okso, -C(O)OH, -C(O)-O-(C1-C3)alkil, -C(O)-O-(C1-C3)alki-aril, -C(O)-O-(C1-C3)alkil-R6, -CONH2,-CONH(C1-C3)alkil, -C(O)NH-aril, -C(O)NH- R6, -CONR5 -CONHNH2,-C(=NH)NH-(C1-C6)alkil, -C(=NH)NH2, C(=NH)NHOH, -C(O)-R8,-C(O)NHSO2(C1-C6) alkil, -C(O)NHSO2-aril, -C(O)NHOH, -C(O)NHSO2-R6, -C(O)NHNH-(C1-C6)alkil, -C(O)NHNH-aril, -CONH-(C1-C2)alkil-aril,-C(O)NH-(C1-C2) alkil-R6, -CH2NR5, -NH2, -NH-(C1-C6)alkil, -NH-C(O)-O-(C1-C3)alkil, -NH-C(O)-(C1-C3)alkil, -NHC(O)-aril, -NHC(O)-(C1-C3)alkilaril,-NHC(O)-R6, -NH-C(O)NR5, -NH-C(O)NH-aril, -NHC(O)NH-(C1-C6)alkil,-NHSO2(C1-C6)alkil, -NH-SO2-aril, -NH-SO2-R6, halo, cijano, -OH, -O-(C1-C6)alkil, -O-aril, -O-heteroaril, -O-(C1-C2)alkil-aril, -SO3H, -SO2NH-aril,-SO2NH-R6 ili -SO2NH-(C1-C6)alkil, R6 ili R7; R5 zajedno sa atomom dušika na kojeg je vezan tvore zasićeni ili nezasićeni (C3-C6) člani prsten, koji može nadalje sadržavati 1-2 heteroatoma odabranih od O, N ili S i koji može biti opcijski supstituiran sa jednim ili više supstituenata odabranih od okso, -COCH, halo,-OH, -O-(C1-C6)alkil, ili -(G1-C6)alkila; R6 je odabran od fenila ili 5-8 članog heteroarila koji sadrži 1-4 heteroatoma odabranih od O, N ili S, pri čemu navedeni heteroaril ili fenilni prsten su opcijski supstituirani sa jednim ili više supstituenata odabranih od halogena, -OH, -O-(C1-C6)alkil, -perhaloalkil, -(C1-C6)alkil, -(C3-C6)cikloalkil, -SO2(C1-C6)alkil, cijano, -COOH, -C(O)O-(C1-C6)alkil, -C(O)O-CH2-aril,-C(O)O-aril, -CONH(C1-C3)alkil, nitro, -NH2, -NH-(C1-C6)alkil, -NHC(O)- (C1-C6)alkil, -NHC(O)-aril, -NHSO2(C1-C6)alkil, -CONH2, -SO2-(C1-C6)alkil,-NHSO2(C1-C6)alkil ili -COR8; R7 je a 3-6 člani heterociklički prsten koji sadrži 1-4 heteroatoma odabranih od O, N ili S, i navedeni heterociklički prsten je opcijski supstituiran sa jednim ili više supstituenata odabranih od okso, halogen, -O-(C1-C6)alkil, -OH,-CF3, (C1-C6)alkil, (C3-C6)cikloalkil, cijano, -COOH, -C(O)O-(C1-C6)alkil,-C(O)O-CH2-aril, -C(O)O-aril, -NH2, -NH-(C1-C6)alkil, -NHC(O)-(C1-C6)alkil,-NHC(O)-aril, -CONH2, -SO2aril(C1-C6)alkil, -SO2-(C1-C6)alkil, -NHSO2(C1-C6)alkil ili -COR8; R8 je amino kiselina koja je vezana kroz atom dušika; Z = O, CH2 ili NH; R4 je odabran od P, Q ili T [image] R9 je odabran od -OH, -O-alkil, -OSO3H, halogen, -C(O)O-(C1-C6)alkil,-C(O)NHR8, -OC(O)-(C1-C6)alkil, -O-perhaloalkil, -OC(O)O-(C1-C6)alkil,-CONR5 ,-NHCO-(C1-C6)alkil, -NHC(O)-O-(C1-C6)alkil, -NHC(O)-O-aril,-NHSO2-(C1-C6)alkil, -NHSO2-aril, -NHCONR5 ili; [image] R10 je odabran od H, Halogen, (C1-C6)alkil, alkoksi, ariloksi, -NHCO-(C1-C6)alkil, -NHSO2-(C1-C6)alkil ili -NH-SO2-aril; R11 je H, (C1-C6)alkil, -CO-(C1-C6)alkil, -SO2-(C1-C6)alkil ili -SO2-aril; G' je odabran od H, halogen ili (C1-C6)alkil; G" je odabran od vodika, (C1-C6)alkil, (C3-C6)cikloalkil, aril, halogen, perhaloalkil, CN, CHO, -(C1-C3)alkilaril, -(C1-C6)alkil-O-(C1-C6)alkil, -CH2R9, -CH2aril, -CH2NR5, -COOH, -C(O)O(C1-C6)alkil, -CONH-(C1-C6)alkil,-CONR5, -SC2NR5, -SO2NH-(C1-C6)alkil, -SO2NH-aril; n može biti jedan ili dva; uključujući njihove farmaceutski prihvatljive soli i njihove hidrate, solvate, atropizomere, regioizomere, enantiomere, diastereomere, tautomere, i njihove polimorfe. 11. The compound of formula (IA) is indicated for use in the treatment of disease states associated with inappropriate thyroid hormone activity selected from obesity, insulin resistance, dyslipidemia, metabolic syndrome, type II diabetes, replacement therapy of elderly people with hypothyroidism, depression, cardiovascular diseases and disorders of the skin by applying a therapeutically effective amount of the compound to living mammals, including human beings: [image] wherein, R1 and R3 are the same or different, and are independently selected from H, (C1-C6)alkyl, (C3-C7)cycloalkyl, halo, CN, CF3, -O-(C1-C6)alkyl, -CO2 -(C1-C6)alkyl, COOH, -CONH-(C1-C6)alkyl, -CONH-aryl, -NH2, -CONH-R6, -CONR5, -C1-C3alkyl-aryl, -(C1-C3) alkyl -R6, -NH-(C1-C6)alkyl, -NHaryl, -NH-SO2-(C1-C6)alkyl, -CH2-NH-(C1-C6)alkyl, -CH2-O-(C1-C6) alkyl, -C1-C3alkyl-NR5, R6, R7, wherein C1-C6alkyl and C3-C7 cycloalkyl is optionally substituted with one or more substituents selected from (C1-C6)alkyl, halo, cyano, -OH, oxo, - COOH, -O-(C1-C6)alkyl, -O-benzyl, -COO-(C1-C6)alkyl, -CONH-(C1-C6)alkyl, -CONR5, -CONH-aryl, -CONH-heteroaryl or -CH 2 NR 5 ; R2 is selected from (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)alkenyl, (C3-C6)alkynyl, -C(O)-(C1-C3)alkyl-COOH, -(C1 - C3)alkyl-COOH, -C(O)-(C1-C3)alkyl-COO-alkyl, -C(O)-C(O)O-(C1-C6)alkyl, -C(O)-( C1-C3)alkyl-NH-(C1-C6)alkyl, -C(O)-O-(C1-C6)alkyl, -C(O)NR5, -C(O)NH-(C1-C6)alkyl , -C(O)-(C1-C3)alkylaryl, -C(O)-(C1-C3)alkyl-R6, R6, R7, wherein said (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)alkenyl, (C3-C6)alkynyl are optionally substituted with one or more substituents selected from perhaloalkyl, Oxo, -C(O)OH, -C(O)-O-(C1-C3)alkyl, - C(O)-O-(C1-C3)alkyl-aryl, -C(O)-O-(C1-C3)alkyl-R6, -CONH2, -CONH(C1-C3)alkyl, -C(O) NH-aryl, -C(O)NH- R6, -CONR5 -CONHNH2, -C(=NH)NH-(C1-C6)alkyl, -C(=NH)NH2, C(=NH)NHOH, -C (O)-R8,-C(O)NHSO2(C1-C6) alkyl, -C(O)NHSO2-aryl, -C(O)NHOH, -C(O)NHSO2-R6, -C(O)NHNH -(C1-C6)alkyl, -C(O)NHNH-aryl, -CONH-(C1-C2)alkyl-aryl, -C(O)NH-(C1-C2)alkyl-R6, -CH2NR5, -NH2 , -NH-(C1-C6)alkyl, -NH-C(O)-O-(C1-C3)alkyl, -NH-C(O)-(C1-C3)alkyl, -NHC(O)-aryl , -NHC(O)-(C1-C3)alkylaryl, -NHC(O) -R6, -NH-C(O)NR5, -NH-C(O)NH-aryl, -NHC(O)NH-(C1-C6)alkyl, -NHSO2(C1-C6)alkyl, -NH-SO2 -aryl, -NH-SO2-R6, halo, cyano, -OH, -O-(C1-C6)alkyl, -O-aryl, -O-heteroaryl, -O-(C1-C2)alkyl-aryl, - SO3H, -SO2NH-aryl, -SO2NH-R6 or -SO2NH-(C1-C6)alkyl, R6 or R7; R5 together with the nitrogen atom to which it is attached form a saturated or unsaturated (C3-C6) membered ring, which may further contain 1-2 heteroatoms selected from O, N or S and which may be optionally substituted with one or more substituents selected from oxo , -COCH, halo, -OH, -O-(C1-C6)alkyl, or -(G1-C6)alkyl; R6 is selected from phenyl or 5-8 membered heteroaryl containing 1-4 heteroatoms selected from O, N or S, wherein said heteroaryl or phenyl ring is optionally substituted with one or more substituents selected from halogen, -OH, -O- (C1-C6)alkyl, -perhaloalkyl, -(C1-C6)alkyl, -(C3-C6)cycloalkyl, -SO2(C1-C6)alkyl, cyano, -COOH, -C(O)O-(C1- C6)alkyl, -C(O)O-CH2-aryl, -C(O)O-aryl, -CONH(C1-C3)alkyl, nitro, -NH2, -NH-(C1-C6)alkyl, -NHC (O)-(C1-C6)alkyl, -NHC(O)-aryl, -NHSO2(C1-C6)alkyl, -CONH2, -SO2-(C1-C6)alkyl, -NHSO2(C1-C6)alkyl or -COR8; R7 is a 3-6 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N or S, and said heterocyclic ring is optionally substituted with one or more substituents selected from oxo, halogen, -O-(C1-C6)alkyl , -OH, -CF3, (C1-C6)alkyl, (C3-C6)cycloalkyl, cyano, -COOH, -C(O)O-(C1-C6)alkyl, -C(O)O-CH2-aryl , -C(O)O-aryl, -NH2, -NH-(C1-C6)alkyl, -NHC(O)-(C1-C6)alkyl, -NHC(O)-aryl, -CONH2, -SO2aryl( C1-C6)alkyl, -SO2-(C1-C6)alkyl, -NHSO2(C1-C6)alkyl or -COR8; R8 is an amino acid that is linked through a nitrogen atom; Z = O, CH 2 or NH; R 4 is selected from P, Q or T [image] R9 is selected from -OH, -O-alkyl, -OSO3H, halogen, -C(O)O-(C1-C6)alkyl, -C(O)NHR8, -OC(O)-(C1-C6)alkyl , -O-perhaloalkyl, -OC(O)O-(C1-C6)alkyl,-CONR5 ,-NHCO-(C1-C6)alkyl, -NHC(O)-O-(C1-C6)alkyl, -NHC (O)-O-aryl, -NHSO2-(C1-C6)alkyl, -NHSO2-aryl, -NHCONR5 or; [image] R 10 is selected from H, Halogen, (C 1 -C 6 )alkyl, alkoxy, aryloxy, -NHCO-(C 1 -C 6 )alkyl, -NHSO 2 -(C 1 -C 6 )alkyl or -NH-SO 2 -aryl; R 11 is H, (C 1 -C 6 )alkyl, -CO-(C 1 -C 6 )alkyl, -SO 2 -(C 1 -C 6 )alkyl or -SO 2 -aryl; G' is selected from H, halogen or (C1-C6)alkyl; G" is selected from hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, halogen, perhaloalkyl, CN, CHO, -(C1-C3)alkylaryl, -(C1-C6)alkyl-O-( C1-C6)alkyl, -CH2R9, -CH2aryl, -CH2NR5, -COOH, -C(O)O(C1-C6)alkyl, -CONH-(C1-C6)alkyl, -CONR5, -SC2NR5, -SO2NH- (C1-C6)alkyl, -SO2NH-aryl, n may be one or two; including their pharmaceutically acceptable salts and their hydrates, solvates, atropisomers, regioisomers, enantiomers, diastereomers, tautomers, and polymorphs thereof. 12. Postupak za dobivanje spoja prema zahtjevu 1, naznačen time da sastoji od: (i) reakcija spoja formule (II) [image] sa spojem formule R2-Y pri čemu Y je odlazna skupina poželjno halogen u prisutnosti pogodne baze u pogodnom otapalu ili; (ii) reakcije spoja formule (III) ili (IX) [image] sa hidrazin hidratom ili pogodno supstituiranim hidrazinom formule R2 NH NH2 ili; (iii) reakcije spoja formule (XIII) R4-CHO XIII sa spojem formule (V) [image] u prisutnosti pogodne baze u pogodnom otapalu na što se nastavlja redukcija sa pogodnim sredstvom za redukciju; ili , (iv) reakcije spoja formule (XV) R4-CH2Y XV pri čemu Y je odlazna skupina poželjno halogen sa spojem formule (V) [image] u prisutnosti pogodne baze u pogodnom otapalu ili; (v) reakcije spoja formule (IV) [image] sa spojem R4OH ili R4NH2 u prisutnosti baze; pri čemu R1 R2, R3 i R4 su kako je definirano u zahtjevu 1.12. The process for obtaining the compound according to claim 1, characterized in that it consists of: (i) reaction of the compound of formula (II) [image] with the compound formula R2-Y wherein Y is a leaving group preferably halogen in the presence of a suitable base in a suitable solvent or; (ii) reactions of compounds of formula (III) or (IX) [image] with hydrazine hydrate or suitably substituted hydrazine of the formula R2 NH NH2 or; (iii) reactions of the compound of formula (XIII) R4-CHO XIII with a compound of formula (V) [image] in the presence of a suitable base in a suitable solvent followed by reduction with a suitable reducing agent; or , (iv) reactions of the compound of formula (XV) R4-CH2Y XV where Y is a leaving group, preferably a halogen with a compound of formula (V) [image] in the presence of a suitable base in a suitable solvent or; (v) reactions of the compound of formula (IV) [image] with the compound R4OH or R4NH2 in the presence of a base; wherein R1 R2, R3 and R4 are as defined in claim 1.
HR20100611T 2007-06-06 2008-06-02 Novel compounds HRP20100611T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN857KO2007 2007-06-06
PCT/IN2008/000345 WO2008149379A2 (en) 2007-06-06 2008-06-02 Novel compounds

Publications (1)

Publication Number Publication Date
HRP20100611T1 true HRP20100611T1 (en) 2010-12-31

Family

ID=39828965

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100611T HRP20100611T1 (en) 2007-06-06 2008-06-02 Novel compounds

Country Status (26)

Country Link
US (2) US8143424B2 (en)
EP (1) EP2061766B1 (en)
JP (1) JP5243537B2 (en)
KR (1) KR101152965B1 (en)
CN (1) CN101772487B (en)
AR (1) AR066155A1 (en)
AT (1) ATE478053T1 (en)
AU (1) AU2008259314B2 (en)
CA (1) CA2698704C (en)
CY (1) CY1110925T1 (en)
DE (1) DE602008002205D1 (en)
DK (1) DK2061766T3 (en)
EA (1) EA019084B1 (en)
ES (1) ES2351274T3 (en)
HR (1) HRP20100611T1 (en)
IL (1) IL202515A (en)
MX (1) MX2009013070A (en)
NZ (1) NZ582273A (en)
PL (1) PL2061766T3 (en)
PT (1) PT2061766E (en)
RS (1) RS51501B (en)
SI (1) SI2061766T1 (en)
TW (1) TWI360541B (en)
UA (1) UA98962C2 (en)
WO (1) WO2008149379A2 (en)
ZA (1) ZA200908760B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724381B2 (en) * 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
CN102844286B (en) * 2010-04-15 2014-12-31 默克专利股份有限公司 Process for the preparation of hydroquinones
US8877795B2 (en) * 2010-05-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
ES2795450T3 (en) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedure to synthesize thyroid hormone analogs and polymorphs thereof
EP3043784B9 (en) 2013-09-09 2019-11-20 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
EP3083639B1 (en) 2013-12-16 2019-05-29 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
CN103992225B (en) * 2014-03-26 2016-01-13 安徽师范大学 A kind of salicylaldehyde derivative and preparation method thereof
JP6543342B2 (en) 2014-08-14 2019-07-10 アルハマドシャー，マモウン，エム． Conjugation of a pharmaceutically active agent with a transthyretin ligand via a regulatable linker to extend serum half life
CN106795120B (en) * 2014-10-31 2020-09-01 豪夫迈·罗氏有限公司 New pyridyloxy- and phenyloxy-pyrazolyl compounds
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
EP3267792A4 (en) 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20180230103A1 (en) * 2015-11-16 2018-08-16 Lonza Ltd Method for preparation of 1-methyl-3-(trifluoromethyl)-1h-pyrazol-5-ol
RU2621163C1 (en) * 2016-02-16 2017-05-31 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Antifibrolytic means
CA3040888A1 (en) 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
MX2021015220A (en) 2017-02-17 2022-12-01 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof.
SG11202009073WA (en) 2018-03-23 2020-10-29 Eidos Therapeutics Inc Methods of treating ttr amyloidosis using ag10
JP7469293B2 (en) 2018-08-17 2024-04-16 エイドス セラピューティクス，インコーポレイティド Preparation of AG10
CA3113743A1 (en) * 2018-09-22 2020-03-26 Torrent Pharmaceuticals Limited Methods of producing pyrazole compounds
WO2020175957A1 (en) * 2019-02-28 2020-09-03 주식회사 마더스제약 Pyrazole amide derivative compound and use of same
WO2023047203A1 (en) 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
CN116063296B (en) * 2021-11-02 2025-08-19 凯思凯迪（上海）医药科技有限公司 Compound serving as thyroid hormone beta receptor agonist and application thereof
US20250171429A1 (en) * 2022-02-23 2025-05-29 Biohaven Therapeutics Ltd. Pyrazolyl compounds as kv7 channel activators
US20250171405A1 (en) * 2022-02-23 2025-05-29 Biohaven Therapeutics Ltd. Pyrazolyl compounds as kv7 channel activators
CN118678954A (en) * 2022-02-23 2024-09-20 拜奥海芬治疗学有限公司 Pyrazolyl compounds as KV7 channel activators
CN116836158A (en) * 2022-03-23 2023-10-03 凯思凯迪（上海）医药科技有限公司 A compound as a thyroid hormone beta receptor agonist and its use
CN114920635B (en) * 2022-04-29 2023-05-12 郑州原理医药研究院有限公司 Preparation method of 4-hydroxy-1-indenone
AR129535A1 (en) 2022-06-21 2024-09-04 Syngenta Crop Protection Ag HETEROCYCLIC BICYCLIC CARBOXAMIDE DERIVATIVES MICROBIOCIDES
EP4608836A1 (en) 2022-10-27 2025-09-03 Syngenta Crop Protection AG Microbiocidal heterobicyclic dihydrooxadiazine derivatives
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7598596A (en) 1995-11-01 1997-05-22 Allergan, Inc. Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
DE69725113T2 (en) 1997-02-25 2004-07-15 Akzo Nobel N.V. Azetidine and pyrrolidine derivatives
NZ506465A (en) * 1998-02-26 2003-08-29 Akzo Nobel Nv Derivatives of azetidine and pyrrolidine
US6240678B1 (en) 1998-07-09 2001-06-05 Karl Heinz Spether Capping head with torque adjustment
ATE272609T1 (en) * 1999-03-01 2004-08-15 Pfizer Prod Inc OXAMIC ACID AND ITS DERIVATIVES AS LIGANDS OF THE THYROID RECEPTORS
EP1185229A1 (en) 1999-06-01 2002-03-13 University Of Texas Southwestern Medical Center Method of treating hair loss
EP1127882A1 (en) * 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
KR100879693B1 (en) * 2001-08-17 2009-01-21 상꾜 아그로 가부시키가이샤 2-Cyclopropyl-6-methylphenol
JPWO2003064369A1 (en) * 2002-01-30 2005-05-26 キッセイ薬品工業株式会社 Novel thyroid hormone receptor ligands, pharmaceutical compositions containing them, and uses thereof
AU2003225305A1 (en) * 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7230025B2 (en) * 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
ITRM20030363A1 (en) 2003-07-24 2005-01-25 Fernando Goglia COMPOSITIONS INCLUDING 3THIODOTYRONIN AND PHARMACEUTICAL USE OF THEM.
CA2606498C (en) 2005-05-26 2016-08-09 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
DE602006016821D1 (en) 2005-07-21 2010-10-21 Hoffmann La Roche PYRIDAZINE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS
EP1928455A1 (en) 2005-08-31 2008-06-11 Bayer Healthcare, LLC Anilinopyrazole derivatives useful for the treatment of diabetes

Also Published As

Publication number Publication date
TWI360541B (en) 2012-03-21
PL2061766T3 (en) 2011-02-28
EP2061766B1 (en) 2010-08-18
CA2698704A1 (en) 2008-12-11
TW200911756A (en) 2009-03-16
US8143424B2 (en) 2012-03-27
IL202515A (en) 2013-07-31
CN101772487B (en) 2014-01-22
HK1129221A1 (en) 2009-11-20
CN101772487A (en) 2010-07-07
NZ582273A (en) 2011-06-30
US8378118B2 (en) 2013-02-19
US20120202816A1 (en) 2012-08-09
DE602008002205D1 (en) 2010-09-30
DK2061766T3 (en) 2010-12-13
WO2008149379A2 (en) 2008-12-11
KR101152965B1 (en) 2012-06-08
AU2008259314A1 (en) 2008-12-11
CY1110925T1 (en) 2015-06-10
EA019084B1 (en) 2014-01-30
EP2061766A2 (en) 2009-05-27
PT2061766E (en) 2010-11-26
RS51501B (en) 2011-04-30
AU2008259314B2 (en) 2011-05-19
IL202515A0 (en) 2010-06-30
SI2061766T1 (en) 2010-12-31
KR20100022104A (en) 2010-02-26
EA200901651A1 (en) 2010-12-30
CA2698704C (en) 2016-01-19
WO2008149379A3 (en) 2009-03-19
UA98962C2 (en) 2012-07-10
ES2351274T3 (en) 2011-02-02
AR066155A1 (en) 2009-07-29
JP2010529108A (en) 2010-08-26
MX2009013070A (en) 2010-01-29
US20100168110A1 (en) 2010-07-01
ATE478053T1 (en) 2010-09-15
JP5243537B2 (en) 2013-07-24
ZA200908760B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
HRP20100611T1 (en) Novel compounds
JP5809267B2 (en) N-((6-Amino-pyridin-3-yl) methyl) -heteroaryl-carboxamides as plasma kallikrein inhibitors
US9622991B2 (en) Hematopoietic growth factor mimetic small molecule compounds and their uses
TWI741377B (en) Enzyme inhibitors
JP2013532713A5 (en)
ES2325045T3 (en) NEW DERIVATIVES OF PIRAZOL HETEROCICLILMETIL SUBSTITUTED AND ITS USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES.
JP6538028B2 (en) Heterocyclic derivative
KR100413154B1 (en) 4-arylamino-methylene)-2,4-dihydro-3-pyrazolones
US7250410B2 (en) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
US20140243324A1 (en) Use of hematopoietic growth factor mimetics
US10781181B2 (en) N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
JP2009519349A (en) Compounds that modulate the CB2 receptor
KR20120117841A (en) Pyrazole compounds as crth2 antagonists
WO2006071940A2 (en) Enzyme modulators and treatments
JP2010513304A5 (en)
JP2010506950A (en) Organic compounds
JP2007502287A (en) Melanin-concentrating hormone receptor antagonist
KR20140097459A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JP2008507528A (en) Substituted pyrazoles, compositions containing such compounds and methods of use
JPH11171865A (en) Fused heterocyclic compound
NZ584573A (en) Heterocyclic compound and pharmaceutical composition thereof
BG65858B1 (en) 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
US20230265068A1 (en) Transient receptor potential canonical 3 inhibitors and methods of use thereof
JP2008516964A5 (en)
JP2004504398A (en) 2- (1H-indol-3-yl) -2-oxo-acetamide having antitumor activity